1 / 11

Cyto Pulse Sciences, Inc

Cyto Pulse Sciences, Inc. A Medical Device and Treatment Development Company. 25 June 2009. Instruments - Therapeutic Production Medical Devices - DNA Vaccine Delivery. 0621. Business Areas. Instruments - Produce/Discover Therapeutics More than 40 Revenue Producing Licenses in Place

glenda
Télécharger la présentation

Cyto Pulse Sciences, Inc

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Cyto Pulse Sciences, Inc A Medical Device and Treatment Development Company 25 June 2009 Instruments - Therapeutic Production Medical Devices - DNA Vaccine Delivery 0621

  2. Business Areas • Instruments - Produce/Discover Therapeutics • More than 40 Revenue Producing Licenses in Place • Growing 40% per year • Development Stage Medical Devices • Deliver DNA/RNA Therapy • Focus on cancer treatment and infectious diseases • Clinical trials in progress • Looking for partners to license

  3. Hybrimune™ mAb Discovery InstrumentA number have multiple licenses Others in negotiation

  4. Large Volume Cyto LVT-P™Therapeutic Production Instrument • Closed sterile transfection system • One 23 minute run produces product for 50k to 100k human vaccine doses • Vaccine production begins fall 2009 • Partner-AlphaVax Human Vaccines • Novartis licenses CMV vaccine(press release 28 Dec 2008) • $20 million payment to AlphaVax • Expected to enter Phase II in 2009

  5. Derma Vax™ – DNA Intradermal Delivery Cancer Immunotherapy Medical Device • Delivery Process • Insert therapetic into skin using hypodermic needle • Insert electrode into skin (2 mm) • Apply voltage waveform (1/3 second) • Waveform generator • Touch screen user input • Computer controlled • Compliance Certified • Electrode single use, sterile and disposable

  6. Clinical Trials - Phase I • 8 Cancer academic collaboratorsLymphoma, prostate, colorectal, breast • 15 Infectious Disease academic collaboratorsHIV, Flu, Hep B, Hep C Need Partners

  7. Easy Vax™ DNA Epidermal DeliveryProphylactic (infectious diseases) System Operation • Load coated array • Insert array into skin • DNA comes off needles • Electric field delivers DNA battery • Sponsor NIAID $5 million • Dengue 4 serotype vaccine • Tested with smallpox (mice) • Human tolerability trial

  8. Easy Vax™ – Current StatusMice and Monkeys - dengue Monkey Response needs optimization

  9. Cyto Pulse Sciences, Inc. • Incorporated 1995 • Maryland C Corp • 15 Employees • Engineers • Biologists • 94 approved vendors • Products in production • Quality & Design Control System • FDA CFR-820 • EU MDD • No institutional investors Headquarters Glen Burnie, MD, USAStockholm, Sweden – Tokyo, Japan

  10. Leadership Team • Management • Richard Walters, BSE, MSEE, MBA, Founder CEO • Alan King, DVM, PhD, Founder VP • Derin Walters, BSE, MBA VP Asian Operations • John B. Burke, MBA, CPA CFO • Anna-Karin Roos, PhD Mgr EU Operations • Board of Directors • Richard Walters Chairman • Harold Chappelear, BS Pharma (former EVP Upjohn) • Daniel Rak, JD • Stephen Schimpff, MD (former CEO UMMC) • Scientific Advisory Board (SAB) • Stephen Schimpff, MD Chairman • Judith Karp, MD, Oncology JHU Med School • Ruben Mezrich, MD, PhD EE, Radiology UM Med School • Carol Tacket, MD, UM Center for Vaccine Dev UM Med School

  11. Thank you to Larta for the Opportunity • Will be around conference and available for discussions

More Related